Objectives: (1) To report the clinical and synovial effects of a platelet-rich product (PRPr) in normal equine joints, (2) to assess the persistence of platelets within synovial fluid after intra-articular injection, (3) to compare responses to different preparations of that product, and (4) to evaluate a gravity filtration system for PRPr preparation in horses.
Study Design: Experimental.
Methods: A platelet-rich saline product (PRPr) was prepared from 7 normal horses using a proprietary preparation device and was divided into 3 treatments: resting, CaCl2 -activated (23 mM, final), and bovine thrombin-activated (10 U/mL, final). Each horse had 3 concurrent randomly assigned intra-articular PRPr treatments administered in their metacarpophalangeal/metatarsophalangeal joints; the fourth limb was injected with saline (0.9% NaCl) solution as a control. Clinical assessments, cytologic analysis of synovial fluid and hemograms were performed at 6, 24, 48, and 96 hours after injection. PRPr composition and growth factor content were analyzed.
Results: The gravity filtration system produced a moderately concentrated PRPr. At 6 and 24 hours, when compared to control values, all PRPr treatments caused a significant increase in synovial WBC concentration (P < .0059) and neutrophil percentage (P < .0005). Bovine thrombin-activated PRPr injection consistently caused increased effusion scores and periarticular signs. At all time points, the synovial WBC concentration after thrombin-activated PRPr was significantly greater (P < .001) than for the control, CaCl2 -activated or resting PRPr. Intact platelets could be observed in synovial fluid for up to 5 days after intra-articular PRPr injection.
Conclusions: Resting and CaCl2 -activated PRPr may be safely used to treat equine joints, but bovine thrombin activation is not recommended at 10 U/mL. A PRPr can be prepared using a gravity filtration system, eliminating the need for centrifugation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1532-950X.2013.12015.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the Effects of Autologous Leukocyte- and Platelet-Rich Fibrin Membranes for Treating Chronic Wounds: A Prospective Study.
Animals (Basel)
January 2025
Department of Veterinary Medicine and Animal Production, University of Naples "Federico II", 80137 Naples, Italy.
(1) Background: The aim of this prospective study was to evaluate the efficacy of topical application of leukocyte- and platelet-rich fibrin (L-PRF) membranes for treating chronic cutaneous wounds in dogs. (2) Methods: Chronic wounds unresponsive to conventional treatments were assessed on digital photographs and classified using the Bates-Jensen Wound Assessment Tool (BWAT). Each lesion was treated with L-PRF membranes.
View Article and Find Full Text PDFPlatelet-Rich Plasma in the Treatment of Diabetic Foot Ulcers.
Adv Skin Wound Care
January 2025
At Mayo Clinic, Rochester, Minnesota, United States, Paul T. Gomez, BS, is Summer Research Fellow, Regenerative Sciences Track, Mayo Clinic Graduate School of Biomedical Sciences; Saranya P. Wyles, MD, PhD, is Consultant, Department of Dermatology; and Karen L. Andrews, MD, is Director, Vascular Ulcer and Wound Healing Clinic/Gonda Vascular Center, and Consultant, Department of Physical Medicine and Rehabilitation. At Mayo Clinic, Jacksonville, Florida, Jennifer R. Arthurs is APRN, Center for Regenerative Medicine; and Alison J. Bruce, MB, ChB, is Consultant, Department of Dermatology.
Background: Chronic nonhealing neuropathic foot ulcers affect approximately 15% to 30% of patients with diabetes mellitus and are associated with significant morbidity and mortality. Although current strategies to address these chronic wounds include a multifactorial approach, clinical outcomes remain poor and warrant improvement. Platelet-rich plasma (PRP), derived from autologous or allogeneic blood, is an emerging regenerative product that aims to serve as an adjuvant to standard diabetic foot ulcer (DFU) treatment.
View Article and Find Full Text PDFThe Impact of Injectable Platelet-rich Fibrin on Orthodontic Tooth Movement during Retraction: A Randomized Controlled Trial.
J Contemp Dent Pract
September 2024
Department of Orthodontics and Dentofacial Orthopedics, Chettinad Dental College & Research Institute, Chengalpet, Tamil Nadu, India.
Aim: This study intended to comprehend the effects of injectable platelet-rich fibrin (i-PRF) on anchor loss and space closure rates during the retraction phase of orthodontic treatment.
Materials And Methods: Twenty-four participants with malocclusion, necessitating extractions and space closure during orthodontic treatment, were enrolled and divided into two groups ( = 12 participants) group A: the experimental group was administered i-PRF on the maxilla/mandible, while group B: the control group did not. Measurements of the rate of space closure, anchor loss, and salivary enzyme activity were done before retraction (T0), after three weeks (T1), after six weeks (T2), and after nine weeks (T3).
Increasing Bone Regeneration in Maxillary Sinus Augmentation Using Platelet-rich Fibrin: An Interventional Pre-Post Study.
J Contemp Dent Pract
September 2024
Department of Pediatrics Dentistry and Orthodontics, Faculty Odonto-Stomatology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam.
Aim: This study aimed to evaluate the impact of a combination of immediate implant placement with maxillary sinus augmentation (MSA) solely using platelet-rich fibrin (PRF) on guided bone regeneration.
Materials And Methods: An interventional before-after (pre-post) study design was used with 30 dental patients (≥18 years of age; 14 males and 16 females) with initial bone heights ranging between 4 and 6 mm. Following the general check-up and the creation of a study model, the planned implant location demonstrated an external right maxilla diameter of more than 5 mm, thereby validating the cone-beam computed tomography (CBCT) radiograph.
Current trends in the design and fabrication of PRP-based scaffolds for tissue engineering and regenerative medicine.
Biomed Mater
January 2025
Ankara University, Tandogan, Ankara, 06100, TURKEY.
Blood-derived biomaterials with high platelet content have recently emerged as attractive products for tissue engineering and regenerative medicine (TERM). Platelet-derived bioactive molecules have been shown to play a role in wound healing and tissue regeneration processes by promoting collagen synthesis, angiogenesis, cell proliferation, migration, and differentiation. Given their regenerative potential, platelet-rich blood derivatives have become a promising treatment option for use in a variety of conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!